MAYO CLINIC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1889-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mayoclinic.org
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 37
- Registration Number
- NCT00408590
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2019-05-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT00407550
- Locations
- ๐บ๐ธ
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
St. John's Wort for Tobacco Cessation
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 118
- Registration Number
- NCT00405912
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT00405548
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 37
- Registration Number
- NCT00405639
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Rituximab in the Treatment of Idiopathic Membranous Nephropathy
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT00405340
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
CellCept in p-ANCA Vasculitis
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT00405860
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Emergency Department Telephone Quitline
Not Applicable
Completed
- Conditions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT00394420
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 270
- Registration Number
- NCT00392379
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธOregon Research Institute, Eugene, Oregon, United States
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 29
- Registration Number
- NCT00390000
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath